Adjuvant therapy for colon cancer: genes, genes... and the patient in the center. Scientific Publication

Apr 20, 2018 | Magazine: Clinical Cancer Research

Rodriguez J (1), Vicent S (2), Chopitea A (1), Ponz-Sarvise M (3).

ABSTRACT

Although molecular subtype-based stratification and genomic signatures of increasing complexity are becoming a new strategy to guide therapeutic decisions in stage II/III colon cancer, several prognostic factors that can be easily obtained from FFPE specimens should be considered in order to create combined models that better define individual patients needs.

CITATION Clin Cancer Res. 2018 Apr 20. pii: clincanres.0818.2018. doi: 10.1158/1078-0432.CCR-18-0818

see publication in pubmed

Our authors

Dr. Silvestre Vicent Cambra Curriculum

Researcher | Principal Investigator Oncogenes and Effector Targets Research Group

Imagen del Dr. Mariano Ponz -Sarvisé, especialista en Oncología Médica de la Clínica Universidad de Navarra. El Dr. Ponz-Sarvisé se dedica preferencialmente a los tumores de páncreas y vías biliares.

Dr. Mariano Ponz-Sarvisé Curriculum

Researcher | Principal Investigator Solid Tumor Research Program